At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
This role reporting to VP of US Cardiology and Established Brands plays a central role in supporting the development of culture and strategy for US CV in additional to managing integration, and driving towards successful execution of business priorities. This Leader will play a critical role for the business as we launch mavacamten, adding to the CV portfolio while continuing to deliver growth for Eliquis.
Responsibilities
* Key member of the US CV/EB Leadership team, creating and driving agenda per the division goals and objectives
* Provide Strategy and Operations support for mavacamten
* Support VP of CV/EB to ensure involvement and preparedness for engagement with broader organization as well as external audiences
* Drive preparation for key senior management reviews and presentations
* Working closely with Eliquis Strat and Ops, Finance and BI&A, ensure full readiness for all financial processes
* Lead strategic and functional planning, responsible for identifying and driving initiatives across multiple key matrix partners to address emerging business trends
* Serve as a critical interface between key matrix partners and the WW team to drive towards strategic areas of focus and identify key issues
* Develop and execute plan for driving innovation and capability development in partnership with WW commercialization operations
Candidate Specifications
* BS/BA degree or equivalent; MBA or advanced degree preferred (eg, Pharm D, PhD)
* 10+ years of relevant marketing/ brand/commercialization management experience
Preferred Qualifications
* Strong written and verbal communication skills, including ability to articulate messages to a variety of audiences
* Experience working with and leading multi-functional teams to accomplish specified goals
* Must possess the ability to build alignment and drive performance across matrix teams through personal influence
* Ability to work independently in a fast moving and increasingly complex environment with limited direction is required
* Strategic, with an ability to take an enterprise view
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Our company is committed to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace adjustments and ongoing support in their roles. Applicants can request an approval of accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or any part of the recruitment process direct your inquiries to adastaffingsupport@bms.com. Visit careers.bms.com/eeo-accessibility to access our complete Equal Employment Opportunity statement.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.